Publications by authors named "N Gossai"
Purpose Of Review: This review summarizes the current novel therapy landscape in pediatric acute lymphoblastic leukemia (ALL), with a focus on key clinical trials which will shape the future direction of care for these children.
Recent Findings: Recent landmark immunotherapy trials in B-ALL have demonstrated significant benefit for children, adolescents, and young adults with relapsed/refractory high-risk leukemia. Due to these successes, current trials are asking the question as to whether immunotherapy can be successfully incorporated upfront.
Introduction: Nelarabine is a guanine nucleoside analog and functions to terminate DNA synthesis in dividing cells. Pre-clinical and clinical studies have shown that it preferentially accumulates in T-cells where it exerts its cytotoxic effects. After generations of treatment protocol advances, it has been incorporated into numerous treatment regimens against T-lineage acute lymphoblastic leukemia/lymphoma (T-ALL/LLy).
View Article and Find Full Text PDFArticle Synopsis
- The study assessed how leukemic involvement in the central nervous system (CNS) affects the prognosis of newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) through two clinical trials (AALL0434 and AALL1231).
- Outcomes indicated that patients with CNS-1 and CNS-2 had similar event-free and overall survival rates, while those with CNS-3 had significantly worse outcomes, despite some receiving cranial radiation therapy (CRT).
- The research found that novel agents like nelarabine improved survival for those with CNS-3 status, but highlighted the need for new treatment strategies given the poor prognosis associated with CNS-3 involvement.